Sanofi, GSK initiate phase III trial of COVID-19 vaccine

By The Science Advisory Board staff writers

May 28, 2021 -- Sanofi and GlaxoSmithKline started their phase III trial to assess the safety, efficacy, and immunogenicity of their recombinant-protein COVID-19 vaccine candidate.

The trial will evaluate how the vaccine targets the original variant, the B.1.351 variant, and other circulating variants.

The enrollment follows positive results from the phase II trial, which showed the vaccine produced strong rates of neutralizing antibody responses in all adult age groups. Pending positive phase III outcomes and regulatory reviews, the vaccine may be approved by the last quarter of 2021.


Copyright © 2021 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?